<SEC-DOCUMENT>0001144204-15-056519.txt : 20150925
<SEC-HEADER>0001144204-15-056519.hdr.sgml : 20150925
<ACCEPTANCE-DATETIME>20150925141059
ACCESSION NUMBER:		0001144204-15-056519
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150921
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150925
DATE AS OF CHANGE:		20150925

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		151124961

	BUSINESS ADDRESS:	
		STREET 1:		450 NORTH BRAND BLVD.,
		STREET 2:		SUITE 600
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203
		BUSINESS PHONE:		818-396-8050

	MAIL ADDRESS:	
		STREET 1:		700 N. BRAND BLVD.,
		STREET 2:		SUITE 220
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v420932_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
September 21, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APOLLO MEDICAL HOLDINGS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt">000-25809</FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>46-3837784</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or Other Jurisdiction</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">of Incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">700 N. Brand Blvd., Suite 220, Glendale,
CA 91203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(818) 396-8050</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant's telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><B>Item&nbsp;5.02.</B></TD>
    <TD><B>Departure of Director of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 21, 2015, Mitchell Creem and
Lance Jon Kimmel resigned as directors of Apollo Medical Holdings, Inc. (the &ldquo;Company&rdquo;), effective immediately. Mr.
Creem resigned in order to pursue other business endeavors. Following Mr. Kimmel&rsquo;s resignation, the law firm of which he
is the founder and managing partner, SEC Law Firm, was engaged as the Company&rsquo;s general outside counsel. Each of Messrs.
Creem and Kimmel indicated that his resignation was not the result of any disagreement with the Board or with the Company's management.
Following these resignations, the Board will reduce the size of the Board to five members, a majority of whom will continue to
be independent as required by the rules of the Nasdaq Capital Market, which had previously granted the Company conditional approval
to list its common stock thereon. That listing has not yet taken place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Also on September 21, 2015, Mr.<FONT STYLE="font-size: 10pt">
</FONT>Creem resigned as Chief Financial Officer of the Company, for the reasons stated in this previous paragraph and not as a
result of any disagreement with the Board or the Company&rsquo;s management. William R. Abbott, the Company&rsquo;s Controller,
has been appointed as Interim Chief Financial Officer. The Company has engaged the services of a leading executive search firm
to find a permanent Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. Abbott joined the Company as Vice President
of Finance and Corporate Controller in December 2014. From 2011 to 2014, he was an independent consultant providing accounting
and advisory services. From 2006 to 2011, Mr. Abbott served as Senior Vice President, Chief Financial Officer, Secretary and Treasurer
for Cardiogenesis Corporation. From 1997 to 2005, Mr. Abbott served in financial management positions at Newport Corporation, including
as Vice President of Finance and Treasurer from 2001 to 2005 and Vice President and Corporate Controller from 1997 to 2001. Prior
to that, Mr. Abbott served as Vice President and Corporate Controller of Amcor Sunclipse North America, Director of Financial Planning
for the Western Division of Coca-Cola Enterprises, Inc. and Controller of McKesson Water Products Company. Mr. Abbott also spent
six years in management positions at PepsiCo, Inc. after beginning his career with PricewaterhouseCoopers, LLP. Mr. Abbott has
a Bachelor of Science degree in accounting from Fairfield University and a Masters in Business Administration degree from Pepperdine
University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%"><B>Item&nbsp;7.01.</B></TD>
    <TD STYLE="width: 89%"><B>Regulation FD Disclosure.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 21, 2015, the Company issued
a press release announcing the management changes described in Item 5.02 of this Form 8-K. A copy of the Company's press release
is furnished with this Form 8-K and attached hereto as Exhibit 99.1. The information in Exhibit 99.1 shall not be deemed &quot;filed&quot;
for purposes of Section 18 of the Exchange Act and shall not be deemed incorporated by reference into any filing under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 11%"><B>Item&nbsp;9.01.</B></TD>
    <TD STYLE="font-size: 10pt; width: 89%"><B>Financial Statements and Exhibits.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-decoration: underline; width: 11%"><U>Exhibit No.</U></TD>
    <TD STYLE="font-size: 10pt; text-decoration: underline; width: 89%"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">99.1</TD>
    <TD STYLE="font-size: 10pt">Apollo Medical Holdings, Inc. Press Release dated September 24, 2015.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><B>APOLLO MEDICAL HOLDINGS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Dated: September 25, 2015</TD>
    <TD NOWRAP STYLE="width: 1%; font-size: 10pt">By:&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1pt solid; font-size: 10pt"><I>/s/ Warren Hosseinion</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Name: Warren Hosseinion</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Title:&nbsp;&nbsp;&nbsp; Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v420932_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_001.gif" ALT="">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APOLLO MEDICAL HOLDINGS ANNOUNCES CHANGES
TO ITS BOARD OF DIRECTORS AND CFO POSITION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Glendale, CA &ndash; (PR Newswire)
&ndash; SEPTEMBER 24, 2015 &ndash; </I><FONT STYLE="color: #365F91">Apollo Medical Holdings, Inc.</FONT></B><FONT STYLE="color: #365F91">
</FONT>(&quot;ApolloMed&quot; or &ldquo;the Company&rdquo;) (AMEH), an integrated population health management company, today announced
the resignation of Mitch Creem as Chief Financial Officer and a director, as well as Lance Jon Kimmel as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mitch Creem has been named the CEO of Integrity
Healthcare, an entity created by New York-based investment firm BlueMountain Capital Management to manage and operate the Daughters
of Charity Health System (&ldquo;DOCHS&rdquo;), a 6-hospital system with its own 200-physician medical foundation. Mark Meyers,
ApolloMed&rsquo;s former Chief Strategy Officer and board member, was also named Chief Operating Officer of Integrity Healthcare.
BlueMountain Capital entered into a deal with DOCHS in July that will provide a $250 million capital injection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lance Kimmel is the founder and has been
the managing partner at SEC Law Firm. His practice focuses on public and private securities offerings, going public transactions,
SEC reporting and mergers &amp; acquisitions. Immediately upon his resignation, Mr. Kimmel was engaged by ApolloMed as its outside
general counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">William Abbott, ApolloMed&rsquo;s current
Controller and Vice President of Finance, has been named Interim Chief Financial Officer, pending completion of a formal search
for a permanent CFO, which is underway. ApolloMed has engaged global executive search firm Spencer Stuart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors will be reduced
to five members, a majority of whom will continue to be independent as required by the NASDAQ Capital Market, which in May 2015
granted ApolloMed conditional approval to list its common stock thereon. That listing has not taken place yet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In commenting on these changes, Warren
Hosseinion, M.D., ApolloMed&rsquo;s Chief Executive Officer stated, &ldquo;I would like to thank Mitch for his service and contributions
to ApolloMed. We wish both Mitch and Mark the best of luck and are proud that two of our alumni are leading the turnaround efforts
at DOCHS. At the same time, we have retained a well-known executive search firm to assist us in finding a new CFO who will be able
to continue to help us grow as we further implement our business model.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;The transition of legal services
is logical at this time given our increased level of business activity. By coordinating outside legal services, Mr. Kimmel will
be able to help us manage those activities and monitor their cost more closely,&rdquo; stated Gary Augusta, Executive Chairman.
&ldquo;These changes will also solidify efforts we are making to build a more cost efficient operating and growth platform as we
venture more into risk-taking reimbursement models and population health management services.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Page </I></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></I></B><I> of </I></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>2</I></B></FONT></P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Apollo Medical Holdings, Inc.
(ApolloMed)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Headquartered in Glendale, California,
ApolloMed is a leading integrated population health management company committed to providing exceptional multi-disciplinary care
in the communities it serves. ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated healthcare
delivery platform comprised of six affiliated and complementary physician groups: ApolloMed Hospitalists, ApolloMed ACO (Accountable
Care Organization), Maverick Medical Group (Independent Physician Association), AKM Medical Group (IPA), ApolloMed Care Clinics
and Apollo Palliative Services. ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care. For more
information, please visit <FONT STYLE="color: Blue"><U>www.apollomed.net</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release may contain forward-looking
statements, including information about management's view of Apollo Medical Holdings, Inc. (&ldquo;the Company&rdquo;) future expectations,
plans and prospects. In particular, when used in the preceding discussion, the words &quot;believes,&quot; &quot;expects,&quot;
&quot;intends,&quot; &quot;plans,&quot; &quot;anticipates,&quot; or &quot;may,&quot; and similar conditional expressions are intended
to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an
action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and
other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those
expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company&rsquo;s
future results. Some factors that could cause actual results to differ materially from those indicated by such forward-looking
statements are set forth in the Company&rsquo;s Annual Report on our amended Form 10-K for the fiscal year ended March 31, 2015,
under the caption &ldquo;Risk Factors&rdquo;, which is on file with the Securities and Exchange Commission and available in the
&ldquo;Investor&rdquo; section of the Company&rsquo;s website under the heading &ldquo;SEC Filings&rdquo;. The forward-looking
statements included in this press release are made only as of the date hereof.&nbsp; The Company cannot guarantee future results,
levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements.
Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by
law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Apollo Medical
Holdings, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>For
More Information, PLEASE CONTACT<FONT STYLE="color: #4D4D4D">:</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Michael Sullivan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&#9;&#9;&#9;&#9;&#9; RedChip Companies Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#9;&#9; 1-800-733-2447 Ext. 115</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#9;&#9; michael@redchip.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.gif" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Page </I></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></I></B><I> of </I></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>2</I></B></FONT></P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
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MX0*:2!#DW0M@OV/> D#@NPZ(38(G& $+HOB!!2S@@8%Y#6,&<IIUN1%\=S,
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M4#O_.X!PL!0 O=/7 #(!/.$Y[HN$N^*&@YJO!Z2!!="20'1[MEVWDA5M\ V
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MM99XLO%WM.:%5:1D/88V%B@0?]=>UD)J!:%P;B5=+6<2:+(@'N D"E=ZO3:
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MLT@?\X8$,'$"80#[]Y+'DP">8''4TYDB$1J_\1N-<3*3M#JLPI@5 2T:<R(
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%)P\( #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.gif
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K1[X"2UA- [VT)[4Z8JOMMMQV2Y*QWGH+;KCDEFONN>BFJ^ZZ[+8[4$  .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
